Addus HomeCare (ADUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 10, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of April 23, 2026, are entitled to vote, with 18,664,776 shares outstanding.
Voting can be done online, by phone, or by mail, and a replay of the meeting will be available for one month.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive compensation on an advisory basis.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by January 4, 2027, and director nominations follow specific bylaw procedures.
Board of directors and corporate governance
The board is divided into three classes, with staggered terms; a majority are independent under Nasdaq rules.
Board leadership combines CEO and Chairman roles, with a Lead Director providing independent oversight.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Government Affairs, all with independent members except Government Affairs.
The board met nine times in 2025, and all directors attended at least 75% of meetings.
No shareholder rights plan is in place.
Latest events from Addus HomeCare
- Achieved $1.4B revenue in 2025 with strong growth, stable margins, and expanding national footprint.ADUS
Investor presentation23 Apr 2026 - Hospice recovery, census growth, and tech-driven hiring fuel expansion amid stable rates.ADUS
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Strong Q4 exit, tech-driven efficiency, and robust growth outlook amid regulatory changes.ADUS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Margins, growth, and M&A drive performance as census rebounds and tech boosts fill rates.ADUS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q4 2025 revenue and EBITDA surged, led by personal care and hospice growth.ADUS
Q4 202524 Feb 2026 - Growth driven by acquisitions, tech, and value-based care, with census recovery expected by 2026.ADUS
Jefferies 2025 Healthcare Services Conference3 Feb 2026 - Q2 revenue up 10.4%, net income $18.1M, major equity raise, Gentiva deal, NY divestiture.ADUS
Q2 20242 Feb 2026 - Strong growth, strategic market exits, and value-based care drive expansion and resilience.ADUS
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 7%, EPS up 13%, with Gentiva deal and NY exit to drive future growth.ADUS
Q3 202416 Jan 2026